Sixteen Weeks Later: Expanding the Risk Period for Multisystem Inflammatory Syndrome in Children

Blake T Cirks; Samantha J Rowe; Sarah Y Jiang; Robert M Brooks; Michael P Mulreany; Wendy Hoffner; Olcay Y Jones; Patrick W Hickey

doi:10.1093/jpids/piab007

Sixteen Weeks Later: Expanding the Risk Period for Multisystem Inflammatory Syndrome in Children

J Pediatric Infect Dis Soc. 2021 May 28;10(5):686-690. doi: 10.1093/jpids/piab007.

Authors

Blake T Cirks^{1

2

3}, Samantha J Rowe¹, Sarah Y Jiang¹, Robert M Brooks¹, Michael P Mulreany^{1

2

4}, Wendy Hoffner^{1

2}, Olcay Y Jones^{1

2

5}, Patrick W Hickey²

Affiliations

¹ Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
² Department of Pediatrics, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
³ Division of Pediatric Infectious Diseases, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
⁴ Division of Pediatric Cardiology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
⁵ Division of Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.

Abstract

Multisystem inflammatory syndrome in children (MIS-C) has been observed in temporal association with coronavirus disease 2019 (COVID-19), typically within 2 to 6 weeks of illness or exposure. We present a case of MIS-C occurring 16 weeks after initial COVID-19 illness to highlight the prolonged period of risk for developing MIS-C.

Keywords: multisystem inflammatory syndrome in children; myocarditis; novel coronavirus 2019; severe acute respiratory syndrome coronavirus 2.

Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2021.

Publication types

Case Reports

MeSH terms

Adolescent
Biomarkers / blood
COVID-19 / diagnosis*
COVID-19 / therapy*
Female
Humans
Prognosis
SARS-CoV-2
Systemic Inflammatory Response Syndrome / diagnosis*
Systemic Inflammatory Response Syndrome / therapy*
Time Factors

Substances

Biomarkers

Supplementary concepts

pediatric multisystem inflammatory disease, COVID-19 related